Cargando…

Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions

This study aims to examine the feasibility of DNA methylation age as a biomarker for symptoms and resilience in cancer survivors with multiple chronic conditions (MCCs). We included ten participants from our parent study, an ongoing randomized control trial study. Participants’ symptoms and resilien...

Descripción completa

Detalles Bibliográficos
Autores principales: Lukkahatai, Nada, Park, Jongmin, Jia, Hejingzi Monica, Martin, Daniel, Li, Junxin, Sheng, Jennifer Yeong-Shin, Gill, Jessica, Saligan, Leorey N., Stearns, Vered, Carducci, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669866/
https://www.ncbi.nlm.nih.gov/pubmed/38002076
http://dx.doi.org/10.3390/biomedicines11113076
_version_ 1785149258359373824
author Lukkahatai, Nada
Park, Jongmin
Jia, Hejingzi Monica
Martin, Daniel
Li, Junxin
Sheng, Jennifer Yeong-Shin
Gill, Jessica
Saligan, Leorey N.
Stearns, Vered
Carducci, Michael
author_facet Lukkahatai, Nada
Park, Jongmin
Jia, Hejingzi Monica
Martin, Daniel
Li, Junxin
Sheng, Jennifer Yeong-Shin
Gill, Jessica
Saligan, Leorey N.
Stearns, Vered
Carducci, Michael
author_sort Lukkahatai, Nada
collection PubMed
description This study aims to examine the feasibility of DNA methylation age as a biomarker for symptoms and resilience in cancer survivors with multiple chronic conditions (MCCs). We included ten participants from our parent study, an ongoing randomized control trial study. Participants’ symptoms and resilience were assessed, and peripheral blood was collected. DNA methylation age calculation was performed using DNAge(®) analysis. Data were analyzed using Spearman’s correlation analysis and the Mann–Whitney U test. Participants in the intervention group tended to have a decrease in DNA methylation age and age acceleration after completing an exercise program (mean difference = −0.83 ± 1.26). The change in DNA methylation age was significantly correlated with the change in resilience score (r = −0.897, p = 0.015). The preliminary results suggest that DNA methylation age can be a potential biomarker for improving resilience in cancer survivors with multiple chronic conditions. This finding is limited by the small sample size, and a larger study is needed.
format Online
Article
Text
id pubmed-10669866
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106698662023-11-16 Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions Lukkahatai, Nada Park, Jongmin Jia, Hejingzi Monica Martin, Daniel Li, Junxin Sheng, Jennifer Yeong-Shin Gill, Jessica Saligan, Leorey N. Stearns, Vered Carducci, Michael Biomedicines Article This study aims to examine the feasibility of DNA methylation age as a biomarker for symptoms and resilience in cancer survivors with multiple chronic conditions (MCCs). We included ten participants from our parent study, an ongoing randomized control trial study. Participants’ symptoms and resilience were assessed, and peripheral blood was collected. DNA methylation age calculation was performed using DNAge(®) analysis. Data were analyzed using Spearman’s correlation analysis and the Mann–Whitney U test. Participants in the intervention group tended to have a decrease in DNA methylation age and age acceleration after completing an exercise program (mean difference = −0.83 ± 1.26). The change in DNA methylation age was significantly correlated with the change in resilience score (r = −0.897, p = 0.015). The preliminary results suggest that DNA methylation age can be a potential biomarker for improving resilience in cancer survivors with multiple chronic conditions. This finding is limited by the small sample size, and a larger study is needed. MDPI 2023-11-16 /pmc/articles/PMC10669866/ /pubmed/38002076 http://dx.doi.org/10.3390/biomedicines11113076 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lukkahatai, Nada
Park, Jongmin
Jia, Hejingzi Monica
Martin, Daniel
Li, Junxin
Sheng, Jennifer Yeong-Shin
Gill, Jessica
Saligan, Leorey N.
Stearns, Vered
Carducci, Michael
Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions
title Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions
title_full Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions
title_fullStr Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions
title_full_unstemmed Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions
title_short Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions
title_sort feasibility of dna methylation age as a biomarker of symptoms and resilience among cancer survivors with multiple chronic conditions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669866/
https://www.ncbi.nlm.nih.gov/pubmed/38002076
http://dx.doi.org/10.3390/biomedicines11113076
work_keys_str_mv AT lukkahatainada feasibilityofdnamethylationageasabiomarkerofsymptomsandresilienceamongcancersurvivorswithmultiplechronicconditions
AT parkjongmin feasibilityofdnamethylationageasabiomarkerofsymptomsandresilienceamongcancersurvivorswithmultiplechronicconditions
AT jiahejingzimonica feasibilityofdnamethylationageasabiomarkerofsymptomsandresilienceamongcancersurvivorswithmultiplechronicconditions
AT martindaniel feasibilityofdnamethylationageasabiomarkerofsymptomsandresilienceamongcancersurvivorswithmultiplechronicconditions
AT lijunxin feasibilityofdnamethylationageasabiomarkerofsymptomsandresilienceamongcancersurvivorswithmultiplechronicconditions
AT shengjenniferyeongshin feasibilityofdnamethylationageasabiomarkerofsymptomsandresilienceamongcancersurvivorswithmultiplechronicconditions
AT gilljessica feasibilityofdnamethylationageasabiomarkerofsymptomsandresilienceamongcancersurvivorswithmultiplechronicconditions
AT saliganleoreyn feasibilityofdnamethylationageasabiomarkerofsymptomsandresilienceamongcancersurvivorswithmultiplechronicconditions
AT stearnsvered feasibilityofdnamethylationageasabiomarkerofsymptomsandresilienceamongcancersurvivorswithmultiplechronicconditions
AT carduccimichael feasibilityofdnamethylationageasabiomarkerofsymptomsandresilienceamongcancersurvivorswithmultiplechronicconditions